Joint Statement Issued on “Three Priorities for Rapidly Expanding Access to COVID-19 Vaccines”
February 28, 2022
Japan Pharmaceutical Manufacturers Association
The Japan Pharmaceutical Manufacturers Association (Chairman: Yasushi Okada; hereinafter “JPMA”) is pleased to announce that it has issued a statement regarding “Three Priorities for Rapidly Expanding Access to COVID-19 Vaccines,” which was drafted by pharmaceutical associations in various countries.
Please click here to view the original text (in English) of this joint statement.
“Three Priorities to Urgently Increase Access to COVID-19 Vaccines”
Please refer
to the attached document*
for the Japanese translation of this joint statement.
* The attached document is a Japanese translation and adaptation of the press release issued by pharmaceutical associations in various countries on February 25, 2022, provided for your reference.The official language is English, and the English text shall take precedence regarding the content and interpretation of this document.
The JPMA will continue to collaborate with various relevant stakeholders and engage in support activities aimed at improving vaccine equity.